OPA1 and Alzheimer disease: In contrast to CFA, we did not observe a significant decrease in CFM in 14‐month 5XFAD control AAV animals compared to Ntg controls, suggesting that DLGAP2 overexpression accelerates AD‐related impairment of CFM at 14 months of age.